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Abstract
Background: Estrogen receptor α (ERα) is a transcription factor whose activity is affected by
multiple regulatory cofactors. In an effort to identify the human genes involved in the regulation of
ERα, we constructed a high-throughput, cell-based, functional screening platform by linking a
response element (ERE) with a reporter gene. This allowed the cellular activity of ERα, in cells
cotransfected with the candidate gene, to be quantified in the presence or absence of its cognate
ligand E2.
Results:  From a library of 570 human cDNA clones, we identified zinc finger protein 131
(ZNF131) as a repressor of ERα mediated transactivation. ZNF131 is a typical member of the BTB/
POZ family of transcription factors, and shows both ubiquitous expression and a high degree of
sequence conservation. The luciferase reporter gene assay revealed that ZNF131 inhibits ligand-
dependent transactivation by ERα in a dose-dependent manner. Electrophoretic mobility shift assay
clearly demonstrated that the interaction between ZNF131 and ERα interrupts or prevents ERα
binding to the estrogen response element (ERE). In addition, ZNF131 was able to suppress the
expression of pS2, an ERα target gene.
Conclusion: We suggest that the functional screening platform we constructed can be applied for
high-throughput genomic screening candidate ERα-related genes. This in turn may provide new
insights into the underlying molecular mechanisms of ERα regulation in mammalian cells.
Background
Estrogen plays important roles both in reproductive phys-
iology and in numerous human disease states [1,2]. Estro-
gen exerts its biological actions by binding to two
structurally and functionally distinct estrogen receptors
(ER), α and β [3-5]. ERα is the major ER in human mam-
mary epithelium. After binding with estrogen, it under-
goes an activating conformational change that promotes
its homodimerization and nuclear transportation. In the
nucleus, the dimer is able to bind, with high affinity, to
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cis-acting enhancers known as estrogen response elements
(ERE), which lie within the regulatory regions of target
genes. The classical ERE, originally discovered in the
Xenopus vitellogenin gene, consists of a 13-nucleotide
inverted palindromic sequence separated by any three
nucleotides (5' GGT CAN NNT GAC C 3') [6].
Through its mitogenic effect, estrogen is thought to play a
role in breast cancer development [7,8]. As many as 70%
of patients with breast cancer are estrogen-receptor posi-
tive [9]. ERs may play different pathophysiological roles at
different stages of tumor progression, and may also be
responsible for the increased incidence of breast cancer
following hormone replacement therapy [10]. Although
several pathways have been reported, the E2-ER-ERE path-
way is believed to be responsible for the mitogenic effect
of estradiol and to play a crucial role in regulating its
oncogenic expression [11].
ERα activity can be regulated by a multitude of coregula-
tory factors, termed coactivators and corepressors [12].
Although the biological role of estrogen-mediated activa-
tion of genes is well established, the significance of repres-
sion has only recently begun to be appreciated. ERα
repressors are proposed to provide a counterbalance to
estrogen-induced transactivation, and represent a mecha-
nism that may be employed by the cell for tumor suppres-
sion [13].
The breast cancer and ovarian susceptibility gene 1
(BRCA1) has been shown to inhibit ERα signaling by
repressing the AF-2 domain of ERα, which is linked to the
ligand-binding domain. BRCA1 inhibits the estrogen-
stimulated expression of pS2, cathepsin D, and a variety of
other estrogen-responsive genes in this way [14]. The find-
ing that BRCA1 is a corepressor of ERα provides a poten-
tial molecular explanation for the tissue-specific nature of
BRCA1-associated cancer. However, cancer-causing muta-
tions of BRCA1 only account for 5–10% of breast cancer.
Therefore, it is conceivable that additional factors having
a similar corepressor activity may participate in the same
regulatory process, and that defects in these may contrib-
ute to the etiology of some forms of breast cancer. Thus,
our efforts have been devoted to identifying novel human
genes, which, like BRCA1, repress ERα activity.
Genetic screen in various model organisms is one means
to identify useful genes from the flood of sequence infor-
mation from the various genome projects [15-17]. Recent
advances in cell-based, genetic, high-throughput screen-
ing provide an efficient approach to explore gene function
and disease relevance [18]. These strategies offer the
advantages of speed, cost-effectiveness, genome coverage,
and immediate biological relevance [19,20]. In an effort
to identify human genes involved in regulating activity of
ERα, we constructed a high-throughput, cell-based func-
tional screening platform by linking a response element
(ERE) with a reporter gene. This has enabled us to make a
quantitative assessment of the effect of candidate genes on
the cellular activity of ERα, in the presence or absence of
its cognate ligand E2. We describe here the identification
and characterization of ZNF131, a novel repressor of ERα
mediated transactivation. In addition, the mRNA and pro-
tein levels of pS2/TFF1, an estrogen responsive gene, were
downregulated by ZNF131.
Methods
Plasmids
We constructed a cDNA library from the human RefSeq
database http://www.ncbi.nlm.nih.gov/projects/RefSeq/.
We selected candidate sequences with "Hypothetical",
"Predicted", "Putative", or "Unknown" in their definition,
or candidates with fewer than three functional research
articles. The full-length cDNA of these candidate genes
was inserted into the mammalian expression vector
pcDNA3.1/myc-His (-) B (pcDB) (Invitrogen, USA) [19].
This cDNA library, containing 570 genes, was then
screened. The reporter plasmid pGL4-ERE-LUC was
obtained by inserting the following two annealed oligo-
nucleotides between the Xho I-Hind III sites of the multi-
ple cloning site of the luciferase reporter vector pGL4-
basic (Promega, Madison, WI): 5' TCG AGA GGT CAC
AGT GAC CTA GGT CAC AGT GAC CTA GAT CTG GGC
ATA TAA TGGA-3' and 5'-AGC TTC CAT TAT ATA CCC
AGA TCT AGG TCA CTG TGA CCT AGG TCA CTG TGA
CCTC-3'. This sequence contains two tandem repeats of
the consensus ERE oligonucleotide sequence (AGGT-
CACAGTGACCT) upstream of the minimal human E1B
TATA promoter sequence (GGGCATATAAT) [21]. Expres-
sion vector hERα was generously provided by Dr. Ann M.
Nardulli, University of Illinois, USA. Dr. Richard Baer,
Columbia University Medical center, USA, kindly pro-
vided the BRCA1 expression plasmid. The pRL-TK plas-
mid, which contains the Renilla luciferase gene, was used
as an internal control and was purchased from Promega
(Madison, WI).
Cell culture, transient transfection and dual-luciferase 
reporter assay
HeLa cells were maintained in DMEM (HyClone, Logan,
UT, USA) supplemented with 10% fetal bovine serum.
MCF-7 cells (purchased from ATCC, HTB-22) were main-
tained in DMEM containing 10% fetal bovine serum and
10 μg/ml insulin (Sigma-Aldrich, St. Louis, MO, USA). All
cells were incubated in a 5% CO2 incubator at 37°C.
Depletion of hormone ligands for steroid receptor activa-
tion studies was achieved by cell culture in estrogen-
depleted media (prepared without phenol red and supple-
mented with 10% charcoal/dextran-treated fetal bovine
serum [HyClone]).BMC Genomics 2008, 9:476 http://www.biomedcentral.com/1471-2164/9/476
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For reporter gene assays, HeLa cells were seeded on 96-
well plates in DMEM lacking phenol red and supple-
mented with 5% charcoal/dextran-treated FBS. After 18 h,
the cells were transfected using the Vigorous transfection
reagent (Vigorous Instruments Co., Ltd., China). A total of
95.1 ng plasmid DNA per well were used, comprising 40
ng pGL4-ERE-LUC, 5 ng pRL-TK, 0.1 ng ERα and 50 ng of
the candidate gene. 24 h later, the transfected cells were
treated with 100 nM 17β-estradiol (E2, Sigma) or 0.1%
vehicle (ethanol) for 12 h. Each experiment of non-stim-
ulation and stimulation was performed in triplicate wells.
Firefly luciferase activity was detected with the Dual-Glo
Luciferase Assay Kit (Promega, USA), using a GENios Pro
reader (Tecan, Mannedorf, Zurich, Switzerland), and cor-
rected for transfection efficiency against Renilla luciferase
activity.
Electrophoretic mobility shift assay (EMSA)
The labeled probe was prepared by annealing two oligo-
nucleotides (5'-TCG AAA AGT CAG GTC ACA GTG ACC
TGA TCA ATC GA-3' and 5'-TCG ATT GAT CAG GTC ACT
GTG ACC TGA CTT TTC GA-3') containing the Xenopus
vitellogenin A2 ERE gene, filling in the 3' overhang in the
presence of biotin [22,23]. HeLa cells were estrogen-
depleted for 3 days, then transfected with ERα and pcDB
or the ZNF131 expression construct (pcDB-ZNF131)
using a BTX ECM 830 Square Wave electroporator (Gene-
tronics Inc., SanDiego, CA) (120 V, 20 ms, 2 mm gap
cuvette). 24 h later, cells were treated with 10 nM or 100
nM E2 for 6 h to increase nuclear localization of the ERα.
The nuclear protein extracts were prepared with the NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Pierce,
Rockford, IL). Protein-DNA binding was measured,
briefly, as follows, using the LightShift™ Chemilumines-
cent EMSA Kit (Pierce, Rockford, IL): equal amounts (10
μg) of nuclear extract protein were used in each reaction,
extracts were preincubated with a binding buffer contain-
ing 50% glycerol, 50 ng/μl polydI-dC, 1% NP40 and
Biotin end-labeled probe at 4°C for 20 min, then at room
temperature for 30 min, in a total volume of 20 μl. A 200-
fold excess of non-labeled ERE probe was added in some
of the experiments. The samples were loaded onto prerun
5% polyacrylamide gels under nondenaturing conditions.
After electrophoresis, gel was transferred to Biodyne nylon
membrane (Pierce, Rockford, IL, USA). Subsequent steps
were performed as instructed by the manufacturer
(Pierce).
Western blot analysis
Cell culture and transfection conditions were identical to
those described above for EMSA analysis. After transfec-
tion with ERα and the indicated plasmids for 24 h, the
cells were incubated with 100 nM E2 or vehicle for 12 h,
then lysed with RIPA buffer (150 mM NaCl, 1% NP40,
0.5% sodium deoxycholic acid, 0.1% SDS and 50 mM
Tris-HCl with freshly added proteinase inhibitor cocktail)
for 30 min on ice. The supernatant protein concentration
was measured using a BCA protein assay kit (Pierce). 30
μg total protein was separated by SDS-PAGE (10%). The
antibodies used for immunoblotting were purchased
from Santa Cruz (CA, USA): goat anti-pS2 (sc-22501),
rabbit anti-ERα (H-184), goat anti-cathepsin D (sc-6486),
and mouse anti-β-actin (sc-47778). Immunoblotting for
β-actin was performed to ensure equivalent amounts of
loaded protein. The densitometric analysis of western
blots was performed using Bio-Rad Quantity One compu-
ter software.
RT-PCR analysis
RNA was extracted using Trizol reagent (Invitrogen)
according to the instructions of the manufacturer. RT-PCR
was performed by generating cDNA using the First Strand
cDNA Synthesis kit (Invitrogen). Primers used for pS2
were forward 5'-GCT TCT ATC CTA ATA CCA TCG ACG-
3' and reverse 5'-ATT TTG AGT AGT CAA AGT CAG AGC-
3', which amplified a fragment between positions 243 and
461 of the pS2 mRNA. 36B4 cDNA (coding for the human
acidic ribosomal phosphoprotein PO) was used as an
estrogen-independent mRNA control [24]. The 36B4 for-
ward primer was 5'-CTC AAC ATC TCC CCC TTC TC-3';
the reverse was 5'-CAA ATC CCA TAT CCT CGT CC-3'. The
relative induction levels of pS2 mRNA were calculated
using the Automated DNA/RNA electrophoresis HAD-
GT12 (eGene, USA).
Expression of the human ZNF131 gene was measured in
multiple cell lines and multiple human tissue cDNA
libraries. Primers used for ZNF131 were forward 5'-CCG
ATT GAA TGA ACA GCG-3' and reverse 5'-CTC CTG TTT
GCT CGT GGG-3', while those used for GAPDH were for-
ward 5'-GGG AGC CAA AAG GGT CAT CAT CTC-3' and
reverse 5'-CCA TGC CAG TGA GCT TCC CGT TC-3'.
Statistical analysis
All experiments were repeated three times. All data col-
lected from the luciferase activity assays, EMSA, western
Blot analysis and RT-PCR were expressed as mean ± SD.
The data presented in some figures are from representa-
tive, repeatable experiments. Statistical significance was
determined using the Student's two-tailed t-test.
Bioinformatics analysis of positive genes
Chromosomal localization and gene structure were ana-
lyzed with reference to the high-throughput genomic
sequence database http://www.ncbi.nlm.nih.gov. Expres-
sion profiles were searched for using GNF SymAtlas v1.0.4
http://symatlas.gnf.org/SymAtlas/. The putative cleavage
site of signal peptides was predicted using the Signal P
server http://www.cbs.dtu.dk/services/SignalP. PSORT II
http://psort.nibb.ac.jp/ software was used to analyze theBMC Genomics 2008, 9:476 http://www.biomedcentral.com/1471-2164/9/476
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protein localization. Protein domains were searched by
the National Center for Biotechnology Information Con-
served Domain Database http://www.ncbi.nlm.nih.gov/
Structure/cdd/cdd.shtml[19].
Results
High-throughput cell-based screening reveals a role for 
ZNF131 in regulating the activity of ERα
Our screen for estrogen-suppressing genes involved
cotransfecting them into HeLa cells along with both hERα
and an ERE-luciferase reporter construct (pGL4-ERE-
LUC). Candidate ER-repressor gene cDNAs were cloned
into the mammalian expression vector pcDB; this empty
vector and BRCA1 were used as the negative and positive
control, respectively. Reporter gene activity was first nor-
malized to Renilla luciferase activity obtained by cotrans-
fection of an internal control pRL-TK expression plasmid.
As shown in Fig. 1A, in the presence of 17β-estradiol (E2),
BRCA1 decreased the transcriptional activity of ERα to an
average level of 60%. We decided that candidate genes
that were able to repress ERα activity to this degree or fur-
ther would be selected for further validation. From a
library of 570 clones tested, we identified 8 candidate
clones in the first round of screening (Fig. 1A, Additional
Material). Four of the 8 candidates (TRAF3IP3, ING4,
ZNF131, and PHF7) were validated as ERα pathway
repressors in the triplicate verification assays (Fig. 1B);
their bioinformatics analyses are shown in Table 1.
Human zinc finger protein 131 (ZNF131) was identified
as the strongest ERα transcription repressor (33%) and
was selected for further analysis.
A dose-response assay was constructed by transfecting a
range of amounts, from 0 to 1000 ng, of the ZNF131
expression vector in the assay (pcDB was added as neces-
sary to ensure equal amounts of DNA in each transfec-
tion). Fig. 1C shows that ZNF131 decreased ERα
transcriptional activity in a dose-dependent manner.
Effect of ZNF131 on the binding of the E2-ER complex to 
ERE
To determine how ZNF131 might affect the estrogen sign-
aling pathway, we used an electrophoretic mobility shift
assay (EMSA) to evaluate estrogen-dependent binding of
ERα to the ERE of the Xenopus vitellogenin A2 gene in
nuclear extracts of HeLa cells. As with our screening assay,
cells were transfected with exogenous ERα and ZNF131/
pcDB plasmids, and then treated with the indicated con-
centration of E2. Fig. 2 shows that ZNF131 inhibited the
binding of the E2-ERα complex to ERE. In nuclear extracts
from pcDB-transfected cells, an intense band, correspond-
ing to the ER-ERE complex, was apparent. The intensity of
this band was increased in the presence of an increased
concentration of E2. Cotransfection with ZNF131 signifi-
cantly reduced the intensity of the ER-ERE band. A greater
reduction in band intensity was seen when the concentra-
tion of E2 was raised, suggesting that the inhibition of
ERα-ERE binding by ZNF131 is dependent upon the level
of E2. The specificity of binding was confirmed by the dis-
appearance of the band in the presence of excess unla-
belled oligonucleotide corresponding to ERE.
ZNF131 inhibits expression of pS2
We next determined whether the ZNF131-mediated inhi-
bition of transcriptional activity might extend to other
natural estrogen regulatory sites. We first examined the
effect of ZNF131 on the expression of pS2, a faithful
endogenous ERα-responsive gene whose expression has
been widely used as a marker to monitor the regulatory
effect of estrogen [25-27]. Fig. 3A shows that the protein
level of pS2 was upregulated by the addition of 10 nM
estradiol to HeLa cells transfected with pcDB and exposed
to exogenous ERα. Coincident overexpression of either
ZNF131 or BRCA1 reduced the level of pS2 protein to
almost undetectable levels compared to cells transfected
with the control vector. RT-PCR and capillary electro-
phoresis were also utilized to make quantitative analysis.
Consistent with the findings from the western blot assay,
ZNF131 reduced pS2 mRNA level by 58% in HeLa cells in
the presence of 10 nM estradiol (Fig. 3B).
To confirm these observations under biological relevant
conditions, we repeated these experiments in MCF-7 cells,
in which the expression of pS2 is known to be normally
controlled by estrogen (Fig. 3C). We found that, in these
cells, pS2 expression in the absence of estrogen was
decreased by ZNF131, but not by BRCA1. The addition of
estrogen led to an increase in pS2 protein level, which was
suppressed in the presence of either ZNF131 or BRCA1
(Fig. 3C).
Expression profile of ZNF131
A bioinformatics analysis suggested that ZNF131 is ubiq-
uitously expressed as a member of the POZ-ZF family of
transcription factors. Hybridization experiments based on
human-tissue-expression blots have shown ZNF131 to be
expressed at the highest levels in brain, testis, thymus, and
central nervous system [28]. We further studied the distri-
bution of human ZNF131 mRNA across multiple tissues
by RT-PCR (Fig. 4A). Consistent with the published
results, ZNF131 was detected in many tissues, with high-
est levels in brain, testis, and thymus. We also found
ZNF131 to be highly expressed in lung tissue. Examina-
tion of ZNF131 expression in multiple cell lines, showed
ZNF131 to be expressed in all but SH-SY5Y and B16F10
cells (Fig. 4B).
Discussion
Estrogen receptor α (ERα) signaling pathway is important
for normal mammary gland development and the onsetBMC Genomics 2008, 9:476 http://www.biomedcentral.com/1471-2164/9/476
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High-throughput screening of ERE reporter activity inhibitors in HeLa cells Figure 1
High-throughput screening of ERE reporter activity inhibitors in HeLa cells. (A) Candidate genes, cloned into the 
mammalian expression vector pcDNA3.1 (pcDB), were tested for their ability to inhibit the response, to 17β-estradiol (10 
nM), of and ERE-luciferase reporter. Cells cultured in 96-well plates were co-transfected in parallel with plasmids of pGL4-ERE-
LUC, pRL-TK, ERα and candidate gene or pcDB. Results were corrected for transfection efficiency against Renilla luciferase 
activity. Activity in the presence of the empty pcDB vector alone was given an arbitrary value of one. BRCA1, the positive con-
trol, yielded a luciferase activity of 0.6 (red arrow). 8 clones in the first round of screening exhibited chemiluminescence values 
lower than this (red spots). (B) 4 of the 8 candidate genes (TRAF3IP3, ING4, ZNF131, and PHF7) passed a repeat triplicate 
screening, with ZNF131 identified as the most potent ERα transcription repressor. (C) ZNF131 repressed ERα transcriptional 
activity in a dose-dependent manner. HeLa cells were transiently transfected with pGL4-ERE-LUC (40 ng), pRL-TK (5 ng), ERα 
(0.1 ng) and increasing amounts (0, 10, 25, 100, 250, and 1000 ng) of ZNF131 expression plasmids. Cells were treated with 10 
nM 17β-estradiol (E2). Data in (B and C) are presented as mean ± SD of three independent experiments. (*, significant differ-
ence from control values; P < 0.05)BMC Genomics 2008, 9:476 http://www.biomedcentral.com/1471-2164/9/476
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of breast cancer. The best-characterized corepressor,
NcoR, can interact with ERα in the presence of ERα antag-
onists. Antiestrogen drugs include agents such as
tamoxifen, toremefene, raloxifene and fulwestrant. The
clinical use of antiestrogens is currently limited to com-
pounds that block the interaction of estrogens of all
sources with the ERα. Although these compounds are use-
ful, none identified to date is purely antiestrogenic, and
their clinical effectiveness varies [29]. Currently, both
tamoxifen and raloxifene are most frequently used in
breast cancer chemoprevention. However, tamoxifen's
antagonist activity was abolished in NcoR -/- mouse
embryo fibroblasts (MEFs) [30], and raloxifene did not
provide protection against noninvasive carcinoma as
observed in the CORE trial [31]. Thus, finding more ERα
repressors might be help in designing therapeutic strate-
gies directed toward epigenetic mechanisms in prevention
or treatment of breast cancer.
In the present study, we constructed a high-throughput,
cell-based functional screening platform by linking a
response element (ERE) to a reporter gene, which allowed
us to quantitatively analyze the cellular activity of ERα in
cells cotransfected with the candidate genes, in the pres-
ence or absence of its cognate ligand E2. We first had to
choose an appropriate cell line in which to carry out the
assays. Cell transfection efficiency, convenience, and cost
were each taken into account. The ERα positive breast can-
cer cell lines MCF7 and T47D are frequently used to study
the influence of genes on the function of ERα. However,
the poor transfection efficiency achievable using conven-
tional transfection reagent in these cell lines prompted us
to seek a substitute. We chose HeLa cells because they
offer good transfection efficiency and are strictly ERα AF-
2 permissive [32]. Because HeLa cells are ERα-negative,
our assay required cotransfection of a plasmid expressing
ERα (hERα). The assay described above confirmed that E2
was able to activate ERα in these cells and ERα exoge-
nously introduced into HeLa cells could restore ERα sign-
aling in response to estrogen.
From an initial screen of a library of 570 human cDNA
clones, we identified four genes for further validation, and
ultimately identified ZNF131 as the strongest repressor of
ERα-mediated transactivation.
ZNF131 is a novel gene whose function is not yet well
understood. It was isolated and chromosomally mapped
in 1995, together with a group of 15 other novel human
zinc finger proteins [33], most of which were considered
to be putative candidate genes for developmental and
malignant disorders. Analysis of the expression profile of
ZNF131 revealed it to be ubiquitously expressed in both
the human and mouse [28], with a highest expression in
adult testis, thymus, and brain. Our results are in agree-
ment with this expression pattern, with the additional
finding of significant expression in lung.
ZNF131 protein has been placed in the superfamily of
POK (BTB/POZ and krüppel) proteins, which contain a
BTB/POZ domain in their N-terminal region as well as 5
typical C2H2 zinc fingers, and an additional C2HC zinc
finger structure, in their C-terminus [28]. In POK proteins,
including ZNF131, the BTB/POZ domain putatively con-
fers a specific nuclear localization pattern and mediates
transcriptional repression [34]. We confirmed the nuclear
localization of human ZNF131 in HeLa cells using a
ZNF131-GFP expression construct (data not shown).
The potency of ZNF131 in inhibiting ERα-mediated tran-
scriptional activity in cultured cells was reflected by its
dose-dependent inhibition of ligand-dependent transacti-
vation of ERα. EMSA assays showed that the addition of
estrogen to HeLa nuclear extracts increased the binding of
ERα to ERE, but that overexpression of ZNF131 impaired
this activation by destabilizing the E2-ER-ERE complex.
The action of ZNF131 was specific, dependent on estra-
diol, and effective even at high estradiol concentrations.
The MCF-7 cell line was among the first ER-positive
human breast cancer cell lines to be characterized as
responsive to the mitogenic effects of estrogens in cell cul-
Electrophoretic mobility shift assay: ZNF131 suppresses  ERα-ERE binding activity Figure 2
Electrophoretic mobility shift assay: ZNF131 sup-
presses ERα-ERE binding activity. EMSA of ERα-ERE 
binding activity using nuclear protein from: (lanes 2 and 3) 
control vector pcDB-transfected cells in the presence of 10 
or 100 nM E2; (lanes 4 and 5) ZNF131-transfected cells in 
the presence of 10 or 100 nM E2; (lane 6) pcDB-transfected 
cells in the presence of 100 nM E2 where the biotin-labeled 
ERE probe was competed with 200-fold molar excess of 
unlabeled ERE probe; and (lane 1) blank control. Results 
shown are representative of three independent experiments.BMC Genomics 2008, 9:476 http://www.biomedcentral.com/1471-2164/9/476
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ZNF131 suppressed pS2 gene expression at both the protein and mRNA levels Figure 3
ZNF131 suppressed pS2 gene expression at both the protein and mRNA levels. (A) Western blot analysis (top) for 
pS2 and exogenous ERα expression in HeLa cells transfected with the empty vector (pcDB), ZNF131, or BRCA1, and treated 
with either E2 (10 nM) or the ethanol vehicle for 12 h. Relative band intensity is shown below. (B) Relative induction of pS2 
mRNA in HeLa cells transfected with either pcDB or ZNF131, in the presence (+) or absence (-) of E2. Values are expressed 
relative to control cultures and represent the mean ± SD of three experiments (*, different from control values; P < 0.05). (C) 
Western blot analysis of pS2 expression in MCF-7 cells transfected with pcDB, ZNF131 or BRCA1, and treated with either E2 
(10 nM) or the ethanol vehicle for 12 h. Relative band intensity analysis using Bio-Rad Quantity One software is shown below. 
Relative band density values varied, but were qualitatively similar across three independent experiments.BMC Genomics 2008, 9:476 http://www.biomedcentral.com/1471-2164/9/476
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ture, as well as in athymic nude mice bearing MCF-7 cell
xenografts [35-37]. Further, MCF-7 cells demonstrate
estrogen-stimulated expression of a number of well-char-
acterized estrogen-responsive genes, including Cathepsin
D and pS2 [14]. Overexpression of ZNF131 in MCF-7 cells
led a marked reduction in the expression of pS2 protein,
but not of Cathepsin D (data not shown). This suggests
that pS2 is a specific target gene of ZNF131. Overexpres-
sion of ZNF131 in HeLa cells also repressed pS2 mRNA
and protein level.
The pS2 gene product is a well-known estrogen-inducible
protein that is expressed in breast and gastrointestinal tis-
sues [38,39]. Expression of pS2 has been used as a marker
of estrogen responsiveness in ER containing breast cancer
cells, and as a candidate indicator of disease progression
to predict the success of antiestrogen therapy. pS2, along
with ERα, represent strongly favorable prognostic index in
breast cancer [40-42]. Although elevated expression of
pS2 predicts a more benign course in breast cancer cases,
the mechanism by which this is regulated in human breast
cancer cells is not yet well understood. Our finding that
overexpression of the ZNF131 protein significantly
reduced the level of pS2 in MCF-7 and HeLa cells might
contribute to an understanding of the expression of pS2 in
normal and neoplastic cells.
Conclusion
In summary, we utilized a high-throughput screening sys-
tem and identified a protein, ZNF131, which represses lig-
and-dependent ERα transactivation and is able to regulate
expression of the estrogen-responsive gene pS2. This
might provide new insight into designing therapeutic and
prognostic strategies of breast cancer. Our observations
suggest that ZNF131 as a new ERα repressor correlates
with pS2, while cell changes induced by gene overexpres-
sion do not necessarily mimic physiological responses in
vivo. It is clear that additional studies need to be con-
ducted to understand the regulatory mechanisms and
physiological roles of ZNF131. Appropriate in vitro exper-
iments might, first, include the inactivation of ZNF131
through RNAi to decrease endogenous protein level. In
addition, ChIP assays might allow further study the mech-
anism of sequential recruitment of ERα-containing pro-
tein complexes to estrogen-target promoters, and allow
investigators to generate libraries of repressor-bound pro-
moters.
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Expression analysis of ZNF131 by RT-PCR Figure 4
Expression analysis of ZNF131 by RT-PCR. (A) Expres-
sion profile of ZNF131 in multiple human tissues: lung, testis, 
liver, kidney, heart, prostate, ovary, skeletal muscle, spleen, 
thymus, and brain. (B) Expression profile in multiple cell lines, 
most of which are malignant: 293, HeLa, SH-SY5Y, HepG2, 
B16F10, Raji, Jurkat, PC3, MCF-7, Cos-7, and PG.BMC Genomics 2008, 9:476 http://www.biomedcentral.com/1471-2164/9/476
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